Published in Heart Rhythm on December 01, 2004
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) | NCT00000556
Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm (2010) 2.42
Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm (2006) 1.86
New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol (2010) 1.27
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm (2008) 1.03
Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ Res (2014) 0.97
Atrial fibrillation and inflammation. World J Cardiol (2010) 0.81
Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. Clin Res Cardiol (2010) 0.79
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation. Exp Clin Cardiol (2009) 0.78
Non-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice. J Interv Card Electrophysiol (2008) 0.77
Arrhythmia pharmacogenomics: methodological considerations. Curr Pharm Des (2009) 0.76
The Role Of Renin Angiotensin System In Atrial Fibrillation. J Atr Fibrillation (2014) 0.75
Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF). Can J Cardiol (2008) 0.75
Atrial Arrhythmias and Electroanatomical Remodeling in Patients With Left Ventricular Assist Devices. J Am Heart Assoc (2017) 0.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Azithromycin and the risk of cardiovascular death. N Engl J Med (2012) 8.18
Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med (2006) 6.83
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet (2007) 5.50
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol (2004) 5.05
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA (2004) 4.71
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04
Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med (2005) 4.04
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res (2004) 3.30
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med (2011) 3.12
Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke (2011) 2.97
Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med (2009) 2.96
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med (2004) 2.80
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA (2011) 2.77
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA (2010) 2.68
Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol (2007) 2.62
Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2007) 2.60
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 2.49
Increased risk of adrenal insufficiency following etomidate exposure in critically injured patients. Arch Surg (2008) 2.38
Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J (2005) 2.31
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 2.23
Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes (2007) 2.17
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol (2002) 2.14
Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. J Trauma (2007) 2.08
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med (2012) 2.08
Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm (2009) 2.00
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 1.99
Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol (2004) 1.97
A computer case definition for sudden cardiac death. Pharmacoepidemiol Drug Saf (2010) 1.97
Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry (2013) 1.95
Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol (2002) 1.95
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes (2009) 1.90
High prevalence of insulation failure with externalized cables in St. Jude Medical Riata family ICD leads: fluoroscopic grading scale and correlation to extracted leads. Heart Rhythm (2012) 1.88
Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm (2006) 1.86
The aprotinin story--is BART the final chapter? N Engl J Med (2008) 1.84
Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2004) 1.84
Regional left atrial voltage in patients with atrial fibrillation. Heart Rhythm (2006) 1.84
Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm (2007) 1.82
Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology (2007) 1.80
Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol (2005) 1.77
Tissue structure and connexin expression of canine pulmonary veins. Cardiovasc Res (2002) 1.77
Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend (2009) 1.77
Arrhythmogenic substrate of the pulmonary veins assessed by high-resolution optical mapping. Circulation (2003) 1.73
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm (2008) 1.72
DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med (2003) 1.70
Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm (2004) 1.70
Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol (2002) 1.70
Improving medication use in newly admitted home healthcare patients: a randomized controlled trial. J Am Geriatr Soc (2002) 1.69
Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med (2005) 1.68
Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res (2008) 1.65
Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care (2007) 1.62
Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol (2005) 1.61
Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet (2005) 1.61
A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm (2007) 1.61
Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J (2005) 1.60
Association of TGFBR2 polymorphism with risk of sudden cardiac arrest in patients with coronary artery disease. Heart Rhythm (2009) 1.59
Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol (2003) 1.59
Resident work hour limits and patient safety. Ann Surg (2005) 1.58
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease. Heart Rhythm (2008) 1.56
Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. Cardiovasc Res (2013) 1.55
Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr (2006) 1.55
Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology (2008) 1.52
The rising prevalence of gastroschisis and omphalocele in Tennessee. J Pediatr Surg (2007) 1.52
Safety profiles and lesion size of different radiofrequency ablation technologies: a comparison of large tip, open and closed irrigation catheters. J Cardiovasc Electrophysiol (2008) 1.51
Trends in healthcare usage attributable to diarrhea, 1995-2004. J Pediatr (2008) 1.46
Prospective observations in the clinical and electrophysiological characteristics of intra-isthmus reentry. J Cardiovasc Electrophysiol (2010) 1.43
Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J (2007) 1.42
Predictors of axillary vein location for vascular access during pacemaker and defibrillator lead implantation. Pacing Clin Electrophysiol (2011) 1.42
Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med (2005) 1.42
Postmarketing surveillance for drug safety: surely we can do better. Clin Pharmacol Ther (2004) 1.41
Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med (2002) 1.40
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J (2005) 1.40
Cardiovascular toxicity of valdecoxib. N Engl J Med (2004) 1.39
A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med (2014) 1.39
Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants. J Perinatol (2004) 1.39
Left ventricular aneurysm as a consequence of hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv (2002) 1.39
Utility of daily supervised hyperventilation during long-term video-EEG monitoring. J Clin Neurophysiol (2009) 1.39
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation (2006) 1.38